ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för retaspimycin hydrochloride. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2012-11-28

Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.

Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R.

Cancer Treat Rev · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.ctrv.2012.10.001

Bibliografisk träff 2012-06-01

Geldanamycin and its derivatives as Hsp90 inhibitors.

Gorska M, Popowska U, Sielicka-Dudzin A, Kuban-Jankowska A, Sawczuk W, Knap N, Cicero G, Wozniak F.

Front Biosci (Landmark Ed) · research support, non-u.s. gov't; review; journal article · DOI 10.2741/4050

Bibliografisk träff 2012-01-10

Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.

Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M.

Int J Oncol · research support, non-u.s. gov't; journal article · DOI 10.3892/ijo.2012.1328

Bibliografisk träff 2011-09-01

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K.

Cancer Cell · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ccr.2011.08.014

Bibliografisk träff 2011-08-18

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.

Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C, Goddard J, Dunbar J, Normant E, Adams J, Grayzel D, Anderson KC, Richardson P.

Leuk Lymphoma · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.3109/10428194.2011.600481

Bibliografisk träff 2011-08-08

The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.

Floris G, Debiec-Rychter M, Wozniak A, Stefan C, Normant E, Faa G, Machiels K, Vanleeuw U, Sciot R, Schöffski P.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-11-0148

Bibliografisk träff 2011-07-18

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW.

Urology · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.1016/j.urology.2011.04.041

Bibliografisk träff 2011-03-07

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.

Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O, Lim AR, Slocum KL, West KA, Rodriguez V, Prudkin L, Jimenez J, Aura C, Baselga J.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-10-0966

Bibliografisk träff 2011-01-24

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, Palombella VJ, Fritz CC.

Oncogene · journal article · DOI 10.1038/onc.2010.625

Bibliografisk träff 2010-11-24

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.

Roué G, Pérez-Galán P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant E, Campo E, Colomer D.

Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2010-04-278853

Bibliografisk träff 2010-10-12

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R.

J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1200/jco.2010.30.8338

Bibliografisk träff 2010-10-12

Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.

Tillotson B, Slocum K, Coco J, Whitebread N, Thomas B, West KA, MacDougall J, Ge J, Ali JA, Palombella VJ, Normant E, Adams J, Fritz CC.

J Biol Chem · research-article; journal article · DOI 10.1074/jbc.m110.141580

Bibliografisk träff 2010-03-01

28th Annual JPMorgan Healthcare Conference--Affymax and Infinity Pharmaceuticals.

Croasdell G, Mason VL.

IDrugs · conference proceedings

Bibliografisk träff 2010-01-01

Gateways to clinical trials.

Tomillero A, Moral MA.

Methods Find Exp Clin Pharmacol · bibliography; journal article

Bibliografisk träff 2009-12-01

The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.

Douglas M, Lim AR, Porter JR, West K, Pink MM, Ge J, Wylie AA, Tibbits TT, Biggs K, Curtis M, Palombella VJ, Adams J, Fritz CC, Normant E.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-09-0568

Bibliografisk träff 2009-09-01

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.

Hanson BE, Vesole DH.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543780903158934

Bibliografisk träff 2009-08-11

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

Leow CC, Chesebrough J, Coffman KT, Fazenbaker CA, Gooya J, Weng D, Coats S, Jackson D, Jallal B, Chang Y.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-08-1038

Bibliografisk träff 2009-01-01

Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy.

Porter JR, Ge J, Lee J, Normant E, West K.

Curr Top Med Chem · review; journal article · DOI 10.2174/156802609789895719

Bibliografisk träff 2008-11-13

The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.

Abramson JS, Chen W, Juszczynski P, Takahashi H, Neuberg D, Kutok JL, Takeyama K, Shipp MA.

Br J Haematol · research-article; journal article · DOI 10.1111/j.1365-2141.2008.07484.x

Bibliografisk träff 2008-10-01

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

Song D, Chaerkady R, Tan AC, García-García E, Nalli A, Suárez-Gauthier A, López-Ríos F, Zhang XF, Solomon A, Tong J, Read M, Fritz C, Jimeno A, Pandey A, Hidalgo M.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-08-0508

Bibliografisk träff 2008-09-01

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, Wozniak A, Schöffski P, Marynen P, Debiec-Rychter M.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-08-0533

Bibliografisk träff 2008-07-31

Targeting Hsp90: small-molecule inhibitors and their clinical development.

Taldone T, Gozman A, Maharaj R, Chiosis G.

Curr Opin Pharmacol · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1016/j.coph.2008.06.015

Bibliografisk träff 2007-07-12

IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells.

Patterson J, Palombella VJ, Fritz C, Normant E.

Cancer Chemother Pharmacol · journal article · DOI 10.1007/s00280-007-0546-0

Bibliografisk träff 2007-03-29

Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.

Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D, Pak R, Read M, Li S.

Blood · research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2006-10-054098

Bibliografisk träff 2006-11-07

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.

Proc Natl Acad Sci U S A · research-article; journal article · DOI 10.1073/pnas.0608372103